Table 2 Comparative mutational analysis as determined by Agena MassArray of mutations in EGFR, ERBB2, ERBB3, ERBB4, PIK3CA, KRAS and BRAF; IC50 values for copanlisib, refametinib, lapatinib, and the effect of trastuzumab on growth inhibition in a panel of gastric cancer cell lines
Cell line | HER2 status | Mutational Status | Response to targeted therapies | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EGFR | ERBB2 | ERBB3 | ERBB4 | PIK3CA | KRAS | BRAF | Copanlisib (nM) | Refametinib (µM) | Lapatinib (nM) | Trastuzumab % growth inhibition at 10 µg/ml | ||
ESO26 | Strongly positive | WT | WT | WT | M772L | Q546H | WT | WT | 43.1 ± 9.6 |  > 10 | 290.8 ± 42.7 | 7.5 ± 5.7 |
NCI-N87 | Strongly positive | WT | F425L L436V | WT | WT | WT | WT | WT | 26.8 ± 9.7 |  > 10 | 39.8 ± 13.3 | 38.6 ± 2.1 |
OE19 | Strongly positive | WT | WT | WT | WT | WT | WT | WT |  > 1000 | 2.75 ± 0.37 | 1660 ± 151.7 | − 1.8 ± 7.6 |
SNU16 | Weakly positive | WT | WT | WT | WT | WT | G12D | WT | 102.6 ± 28.5 | 5.6 ± 1.4 |  > 10,000 | 12 ± 3.1 |
KATOIII | Negative | WT | WT | WT | WT | L387L | WT | WT | 65 ± 23.9 | 6.05 ± 0.84 |  > 10,000 | -2.8 ± 7.4 |